Other languages Bausch + Lomb Corporation Toronto S.E.

Equities

BLCO

CA0717051076

Market Closed - Toronto S.E. Other stock markets 21:10:00 21/06/2024 BST			5-day change	1st Jan Change
20.8 ^CAD	+1.17%		+0.53%	-8.25%

06-17	Bausch + Lomb Brief: To Present New Data at European Dry Eye Society 2024 Congress; Events Include Symposium on Patient-Centric Approaches to Dry Eye, "Highlighting Breakthroughs in Diagnosis, Treatment and Care"	MT
06-10	Bausch + Lomb Corporation Announces the U.S. Introduction of Bausch + Lomb Infuse for Astigmatism Daily Disposable Contact Lenses	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Bausch + Lomb Corporation Announces the U.S. Introduction of Bausch + Lomb Infuse for Astigmatism Daily Disposable Contact Lenses	06-10
Bausch + Lomb Corporation Launches Blink? NutriTears® Clinically Proven Nutritional Supplement for Dry Eyes in the United States	06-03
Bausch + Lomb Corporation Approves Election of Gary Hu as Director	05-29
Bausch + Lomb Corporation Receives Health Canada Approval for Envista Envy?? Full Visual Range Intraocular Lens	05-28
Bausch + Lomb Shares Rise After Morgan Stanley Upgrade	05-06
RBC Capital Reviews Bausch + Lomb's Q1 Results	05-02
Needham Says Bausch + Lomb's Q1 Showed a "Strong Start" to The Year	05-01
Bausch + Lomb Q1 Loss Widens, Revenue Increases	05-01
Bausch + Lomb Q1 Net Loss Widens, But Revenue Higher; Raises 2024 Revenue Growth Guidance	05-01
Bausch + Lomb Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-01
Bausch + Lomb Says Study Shows Improvements in Dry Eyes With Nutritional Supplement	04-25
Bausch + Lomb Corporation Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes	04-25
RBC Previews Bausch Health's Q1, Trims Target to US$11	04-23
Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says	04-12
Bausch + Lomb Corporation Announces Board Changes	02-28
Deutsche Bank on Bausch + Lomb's Q4	02-22
Bausch + Lomb's Likely to Face Market-Related Risks From Spin, RBC Says	02-22
RBC Raises Bausch + Lomb Target to US$20, Reiterates Outperform, After Q4	02-22
Sector Update: Health Care Stocks Mixed in Late Afternoon	02-21
Needham Reviews Bausch + Lomb's Q4	02-21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Bausch + Lomb Corporation Toronto S.E.

Equities

BLCO

CA0717051076

Other languages

Filters